Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma

Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology.
Source: MedWire News - Category: Consumer Health News Tags: Lymphoma Source Type: news

Related Links:

Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsi...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Research Source Type: research
Authors: Wong HK PMID: 30863486 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Cutaneous T-cell lymphomas (CTCL) are a family of primary extranodal lymphomas of mature CD4+, skin-homing or skin-resident T-cells. In a significant fraction of CTCL patients the neoplastic CD4+ lymphocytes acquire extracutaneous tropism, and with disease progression, they disseminate to the lymph nodes, peripheral blood, and visceral organs. MicroRNA (miR)-based therapies are a newly emerging strategy for many types of diseases, including cancers. CTCL represents one of the disease indications for a clinical trial of miR inhibitor therapy, supporting further investigation of epigenetic dysregulation and miR-driven oncoge...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light. “It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg. In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better. Light, we know, plays an important...
Source: Psych Central - Category: Psychiatry Authors: Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news
Monoclonal antibody therapies, such as alemtuzumab, brentuximab vedotin, and mogamulizumab, are showing promise for previously relapsed and refractory CTCL.American Journal of Clinical Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
lls J Abstract Cutaneous T-cell lymphoma is an uncommon group of non-Hodgkin's lymphoma primarily affecting the skin. It is comprised of a variety of entities with different clinical behaviours and prognosis. Mycosis fungoides is the commonest subtype, and Sézary syndrome is a much rarer form of cutaneous T-cell lymphoma. At this stage, control rather than cure is the goal of therapy, with particular emphasis placed on preserving quality of life. Our review of the efficacy, safety profile and accessibility of treatment modalities for mycosis fungoides/Sézary syndrome is a tailored guide for the clini...
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Australas J Dermatol Source Type: research
CONCLUSIONS: These findings can be explained by a model where malignant transformation takes place during early T-cell development giving rise to circulating pre-malignant clones which home to the skin producing clinically apparent lesions of cutaneous lymphoma. Therapeutic strategies in T-cell lymphoma should therefore target those early lymphoma precursor cells. PMID: 30808775 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin–based fusion protein that depletes CD25-positive cells including regulatory T cells and has been approved for the treatment of persistent or recurrent cutaneous T cell lymphoma. However, the clinical use of denileukin diftitox was limited by vascular leak toxicity and production issues related to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
Publication date: Available online 15 February 2019Source: Radiation Physics and ChemistryAuthor(s): S.B. Almeida, D. Villani, R.K. Sakuraba, A.C.P. Rezende, L.L. CamposAbstractThe Total Skin Electron Beam (TSEB) therapy is a technique that aims to provide skin surface homogeneous absorbed dose in order to treat cutaneous T-cell lymphomas, both for curative and palliative purposes with electron beams penetrating a few millimeters into the skin, reaching the affected parts without affecting internal organs. In vivo dosimetry has become an important role for the treatment of total skin irradiation within a rigorous quality a...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
ConclusionThe reason for the association between the high serum copper levels and adverse prognosis is unknown. We hypothesized that interleukin-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of interleukin-6 at the lesion sites might conceivably also promote neoplastic cell progression by stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper levels, interleukin-6, or C-reactive protein and prognosis might be informative.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Health | Lymphoma | T-cell Lymphoma